Moleculin Biotech Inc MBRX 深 滬
等待開盤 08-18 09:30:00 美东时间
0.6825
+0.035
+5.36%
華盛通- 最 高0.6854
- 今 開0.66
- 成交量 76.38万股
- 最 低 0.63
- 昨 收 0.6478
- 總市值 2061.66万
- 52周最高 3.6499
- 市盈率 靜 --
- 換手率 2.53%
- 52周最低 0.25
- 委 比 0.00%
- 總股本 3020.75万
- 歷史最高 862.20
- 量 比 1.02
- 振 幅 8.55%
- 歷史最低 0.25
- 每 手 1
- 風險率 0.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Moleculin Biotech, Inc. (Nasdaq: MBRX) will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 20, 2025, at 2:00 PM ET. Walter Klemp, Founder, President, CEO, and Chairman, will discuss the Company's progress. Moleculin specializes in developing therapies for hard-to-treat tumors and viruses. Its lead candidate, Annamycin, targets relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma ...
08-14 13:15
Moleculin Biotech GAAP EPS of -$0.49
Moleculin Biotech press release (NASDAQ:MBRX): Q2 GAAP EPS of -$0.49. Cash and cash equivalents of $7.6M More on Moleculin Biotech Moleculin receives notice of intent to grant new European patent fo...
08-13 21:45
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
Moleculin Biotech reported Q2 2025 financial results, highlighting progress in its Phase 2B/3 MIRACLE trial evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML). The trial has expanded into additional countries and expects to add over 20 new sites in the EU and US by Q3. Positive topline data from the Phase 1B/2 trial for soft tissue sarcoma lung metastases (STS lung mets) was also reported, with median overall survival of...
08-13 12:05
Moleculin Biotech Q2 EPS $(0.49) Misses $(0.42) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.42) by 16.67 percent. This is a 71.18 percent increase over losses of $(1.70) per share
08-13 05:57
Moleculin Biotech Reveals Promising Preclinical Data for Annamycin
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On August 6, 2025, Mo...
08-06 20:54
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Moleculin Biotech, Inc. has presented encouraging preclinical data for Annamycin (naxtarubicin), showing its potential for treating various liver cancers, including hepatocellular carcinoma, colorectal liver metastases, and pancreatic ductal adenocarcinoma liver metastases. The drug demonstrated targeted accumulation in the liver and other organs, significant anti-tumor activity, and a favorable safety profile with low cardiotoxicity. These resul...
08-06 12:40
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Mainz Biomed announces a $3.0 million follow-on offering of 2,222,222 units at $1.35 per unit, each consisting of one ordinary share or pre-funded warrant and one Series A warrant exercisable at $1.35 per share. The offering, managed by Maxim Group LLC, is set to close on August 5, 2025, pending customary conditions. The securities are registered under SEC's Form F-1 (File No. 333-289095). Investors can obtain the prospectus from Maxim Group.
08-04 14:22
Moleculin Biotech Releases Corporate Presentation Update
Moleculin Biotech ( ($MBRX) ) has issued an announcement. On August 1, 2025, Mo...
08-02 05:27
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Moleculin Biotech's CEO, Walter Klemp, participated in a virtual investor conference, discussing his dedication to the company and its development programs. The on-demand video is available on the company's website. Moleculin is advancing Annamycin, a novel anthracycline for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases, currently in Phase 3 trials. The company is also developing WP1066, an immu...
07-22 12:45
